A Phase 1, Randomized, Two-part Study to Evaluate the Relative Bioavailability of Two Formulations of ALKS 5461 and the Effect of Dose Titration of ALKS 5461 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Two-part Study to Evaluate the Relative Bioavailability of Two Formulations of ALKS 5461 and the Effect of Dose Titration of ALKS 5461 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Buprenorphine/samidorphan (Primary)
  • Indications Cocaine abuse; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Alkermes plc
  • Most Recent Events

    • 18 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 27 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top